We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-7.28%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.53B
AUM Growth
-$382M
Cap. Flow
+$195M
Cap. Flow %
2.99%
Top 10 Hldgs %
59.37%
Holding
305
New
83
Increased
54
Reduced
76
Closed
50

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$108M
2
BUD icon
AB InBev
BUD
+$39.8M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$33.9M
4
CRL icon
Charles River Laboratories
CRL
+$32M
5
CL icon
Colgate-Palmolive
CL
+$27M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$93.3M
2
PFE icon
Pfizer
PFE
+$76.9M
3
JNJ icon
Johnson & Johnson
JNJ
+$53.7M
4
INCY icon
Incyte
INCY
+$46.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$45.7M

Sector Composition

Rank Sector Weight
1 Healthcare 34.38%
2 Consumer Staples 6.6%
3 Technology 4.23%
4 Consumer Discretionary 3.89%
5 Communication Services 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
26
Aurinia Pharmaceuticals
AUPH
$1.87B
$47M 0.72%
6,048,000
+1,356,000
+29% +$13.3M
POST icon
27
Post Holdings
POST
$4.09B
$45.8M 0.7%
533,634
+25,224
+5% +$2.2M
KDP icon
28
Keurig Dr Pepper
KDP
$42.1B
$45.5M 0.7%
1,442,332
+95,332
+7% +$3.15M
KHC icon
29
Kraft Heinz
KHC
$31.3B
$43.4M 0.67%
1,291,008
+441,008
+52% +$15.2M
MSFT icon
30
Microsoft
MSFT
$3.62T
$42.2M 0.65%
133,499
-26,501
-17% -$8.76M
JAZZ icon
31
Jazz Pharmaceuticals
JAZZ
$15.8B
$40.5M 0.62%
312,744
-143,256
-31% -$19.1M
VRTX icon
32
Vertex Pharmaceuticals
VRTX
$119B
$40.4M 0.62%
116,117
-7,883
-6% -$2.76M
IMVT icon
33
Immunovant
IMVT
$7.91B
$39.8M 0.61%
+1,035,877
New +$23.4M
NVO
34
Novo Nordisk
NVO
$208B
$39.6M 0.61%
436,000
-104,000
-19% -$9.16M
PARA
35
DELISTED
Paramount Global Class B
PARA
$39.6M 0.61%
3,071,559
+283,559
+10% +$4.2M
BUD icon
36
AB InBev
BUD
$166B
$38.9M 0.6%
+703,000
New +$39.8M
OFIX icon
37
Orthofix Medical
OFIX
$496M
$38.1M 0.58%
2,964,000
+528,000
+22% +$9.5M
IRWD icon
38
Ironwood Pharmaceuticals
IRWD
$728M
$33.3M 0.51%
+3,456,000
New +$33.9M
VYGR icon
39
Voyager Therapeutics
VYGR
$181M
$32.4M 0.5%
4,178,000
+554,000
+15% +$5.06M
CPB icon
40
Campbell Soup
CPB
$6.67B
$32M 0.49%
778,571
-1,429
-0.2% -$62.5K
SWAV
41
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$31.7M 0.48%
159,002
+9,002
+6% +$2.13M
BMY icon
42
Bristol-Myers Squibb
BMY
$134B
$30.7M 0.47%
529,613
+129,613
+32% +$7.94M
CRL icon
43
Charles River Laboratories
CRL
$11.1B
$30.6M 0.47%
+156,000
New +$32M
XNCR icon
44
Xencor
XNCR
$1.44B
$29.8M 0.46%
1,478,000
+586,000
+66% +$13.3M
DOCU
45
DocuSign
DOCU
$10.5B
$29.5M 0.45%
703,147
+111,147
+19% +$5.45M
S icon
46
SentinelOne
S
$6.87B
$28.5M 0.44%
1,692,497
-403,503
-19% -$6.37M
ISRG icon
47
Intuitive Surgical
ISRG
$135B
$28.4M 0.44%
97,212
+15,212
+19% +$4.75M
CRSP icon
48
CRISPR Therapeutics
CRSP
$4.88B
$27.2M 0.42%
600,012
+100,012
+20% +$5.17M
EVBG
49
DELISTED
Everbridge, Inc. Common Stock
EVBG
$26.1M 0.4%
1,164,000
-36,000
-3% -$929K
ENTA icon
50
Enanta Pharmaceuticals
ENTA
$377M
$23.5M 0.36%
2,100,000
+64,000
+3% +$1.03M
1
2
3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return

Armistice Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Armistice Capital held 305 positions worth $6.53B, down 5.5% from $6.91B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Armistice Capital's Q3 2023 filing shows 83 new, 54 increased, 76 reduced and 50 closed positions. Its largest new stake was AB InBev: 703,000 shares worth $38.9M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $93.3M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 39% a quarter earlier, followed by Consumer Staples and Technology.

  • Armistice Capital's largest Q3 2023 buy was AB InBev: 703,000 shares worth $38.9M.
  • Armistice Capital added most to PTC Therapeutics in Q3 2023, an estimated $108M increase.
  • Armistice Capital's biggest Q3 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $93.3M.
  • Armistice Capital fully exited Pfizer in Q3 2023, selling an estimated $76.9M.
  • Armistice Capital's ten largest holdings make up 59% of its $6.53B portfolio in Q3 2023.
  • Armistice Capital opened 83 new positions and closed 50 in Q3 2023.
  • Armistice Capital's portfolio value fell 5.5% quarter-over-quarter to $6.53B.

Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.